Hepatic Steatosis Secondary to Peptide Receptor Radionuclide Therapy with Somatostatin Analogue

#2159

Introduction: Peptide Receptor Radionuclide Therapy (PRRT) with 177-Lutetium-DOTA-TATE is a therapeutic modality for neuroendocrine tumors. It has some well known side effects, concerning specially the bone marrow (from cytopenias to myelodysplastic syndrome), in addition to mild renal effects. Hepatotoxicity from PRRT is still being studied.

Aim(s): To report a new hepatic collateral effect which has never been previously described in the literature.

Materials and methods: Upper abdomen computed tomography (CT) and magnetic resonance imaging (MRI) of patientes treated between the years of 2010 and 2017 were reviewed. Radiologic criteria for the diagnosis of steatosis were applied on the scans of 62 patients before and up to one year after the end of PRRT. Clinical features and laboratory during this period were also evaluated.

Conference: 15th Annual ENETSConcerence (2018)

Presenting Author: Matheos de Lima B

Authors: Arruda Matheos de Lima B, Gonçalves R, Romano Gaspar P, Linhares Riello de Mello E, Oliveira Albagli R,

Keywords: peptide receptor radionuclide therapy, lutetium, collateral effects, hepatotoxicity, neuroendocrine tumor, hepatic steatosis,